Navigation Links
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Date:8/14/2008

s -- (129,527)

Construction deposits (2,206,145) --

Contractor deposits 101,801 412,802

Addition to construction in progress (9,722,463) (12,961,091)

Proceeds from sale of equipment 61,152 --

Purchase of equipment and automobiles (360,192) (1,158,813)

Net cash used in investing (9,542,428) (18,525,646)

CASH FLOW FROM FINANCING ACTIVITIES:

Loan from (repayment to) related

parties 7,400,000 (843,115)

Payments on long term debt, related

party (1,065,000) --

Proceeds from share subscription in

subsidiary -- 18,000,130

Proceeds from joint venture investor

in Dongfeng 2,828 -

Payment to minority interest

shareholder (5,070,091) (6,676,102)

Net cash provided by (used

in) financing activities 1,267,737 10,480,913

EFFECTOF EXCHANGE RATE CHANGES ON CASH 3,053,932 1,272,215

INCREASE (DECREASE) IN CASH (6,340,515) 3,085,516

CASH, beginning of period 54,081,848 55,214,540

CASH, end of period $ 47,741,333 58,300,056

Supplemental disclosures of cash flow

information

Cash pain during the year for:

Interest (net of amount capitalized) $ 132,662 --

Income taxes $ 1,822,619 1,370,002

Note 1.

On December 20, 2007, the Company's subsidiary, Tianshi International

Holdings Group Ltd. (''Tianshi Holdings''),
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
2. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. ThirdBiotech Announces Kemeta as Newest Sponsor
7. Yongye Biotechnology International Retains CCG Investor Relations
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
10. Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A
11. New Book on the Business of Biotechnology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...BEIJING, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Yon... or "the Company") a leading manufacturer, develop...animal nutrient products in the,People,s Republic ...ct a,conference call at 10:00 a.m. Eastern Time (1...09 to discuss results for the quarter ended Septem...
(Date:11/9/2009)...DIEGO, Nov. 9 NexBio, Inc. announc... American College of Allergy, Asthma, and Immunolo...ed "DAS181 (Fludase®), a Sialidase, Decreases...y Effects in Animal Models of Asthma". ,, DAS18...ectrum host-targeting drug candidate being studied...
(Date:11/9/2009)...LONDON, November 9 Following the p... Food and Drug Administration (FDA), privately,own.../www.davalinternational.com ) has been informed th...R) has been awarded an Orphan-Drug,designation for...LS). , ALS, also known as Lou Gehrig,s di...
(Date:11/6/2009)...NTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Bios...t has re-filed the Form 52-109F1 Certification of ...ive Officer and James Long, the Chief Financial Of... 12, 2009 in connection with the annual audited fi..., 2008. ,, The Company initially filed the annu...
Breaking Biology Technology:Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 3NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3
...ct. 4 Vicus Therapeutics, LLC, an,oncology-focuse...y,announced that John Maki, President and Chief Ex...cussions titled "Outsourcing: Best Practices,and L...Exit Strategies:,Managing Risk and Reward" at BIOT...will run from 9:00 a.m. to 10:15 a.m. ET and from ...
...Newswire-FirstCall/ - Ms. Mary Ann Dillahunty, Vic...iotech Inc. (TSX: ONC,NASDAQ: ONCY), will present ...rForum 2007 on Thursday, October 11 at 12 p.m. PT....n San Francisco from October 9-11, 2007. A live a... on the,company,s website at http://www.oncolytic...
...lude the Recently Released Strong Results from the...pyScore Human Appendicitis Blood... Oct. 4 AspenBio Pharma,Inc. (Nasdaq: APPY ) an ...he,development of novel drugs and diagnostics for ... the Edgewater Research Investor Conference, sched...
Other Biology Technology:Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels 2Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007 2AspenBio Pharma to Present the Edgewater Research Investor Conference 2
(Date:11/8/2009)... , HEALTH EDUCATION DESIGNED FOR ADULTS WITH IN...IER LIVES , An Indiana University study involvi...t the adults increased their personal health knowl...ks. , Adults with ID, an internationally accept...er rates of obesity, physical inactivity and preve...
(Date:11/6/2009)... To celebrate the 150th anniversary this month of...American Institute of Biological Sciences (AIBS) i...s about Charles Darwin and his historic insights i...dian of the University of California, Berkeley, an...adian,s article, "Ten Myths About Charles Darwin,"...
(Date:11/6/2009)...,, DETROIT, Nov. 6 Auburn Hills...C (LEID) will be installing its locker system and ... (BACS) at the U.S. Department of Health and Human...ed in Bethesda, MD. The locker system will suppor...e for protecting our nation,s medical research age...
Breaking Biology News(10 mins):Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3US Oncology Inc Announces 24465 Million Senior Secured Notes Offering 47879 1US Oncology Inc Announces 24465 Million Senior Secured Notes Offering 47879 2Xceed Meets HTX CIHR Grant Milestone 3A Decreasing Sample Prep Time From Days to Less Than Eight Hours 12464 1Xceed Meets HTX CIHR Grant Milestone 3A Decreasing Sample Prep Time From Days to Less Than Eight Hours 12464 2MPR Drug Database Available as a Free Download for Mobile Devices Including BlackBerry and Palm 47875 1MPR Drug Database Available as a Free Download for Mobile Devices Including BlackBerry and Palm 47875 2
...etic Investigation of Anthropometric Parameters) c... So far, the scientists have analyzed two million ...es with a total of more than 32,000 participants. ...ed in 14 further studies including 59,000 particip...y known, it was now possible for six more obesity ...
...w race cars to take tight turns at high speeds. Hi...ages: They are not necessary for basic flight but ...dators. , "To escape a predator, you don,t have to...Tom Eisner, a world authority on animal behavior, ... Professor Emeritus of Chemical Ecology at Cornell...
... 7 WCC Smart Search & Match, the,leading prov..., today,announced that Tarvinder Sembhi has joined... market. , Mr. Sembhi is a veteran executive i...s most recently President of 4G Identity Solutions...evelopment, corporate branding and,marketing, and ...
Other Biology News:Obesity starts in the head? 6 newly discovered genes for obesity have a neural effect 2Hind wings help butterflies make swift turns to evade predators, study finds 2
Chicken Anti-Human AP2M1 Antibody, Unconjugated from ABR-Affinity BioReagents
Human Flt-3/Flk-2 Ligand from eBioscience
Rabbit Anti-GJB2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rabbit Anti-IKKbeta / IKK-2 Polyclonal Antibody, Unconjugated from BioVision
Biology Products: